TY  - JOUR
A1  - Zhou, Xiang
A1  - Steinhardt, Maximilian Johannes
A1  - Düll, Johannes
A1  - Krummenast, Franziska
A1  - Danhof, Sophia
A1  - Meckel, Katharina
A1  - Nickel, Katharina
A1  - Grathwohl, Denise
A1  - Leicht, Hans‐Benno
A1  - Rosenwald, Andreas
A1  - Einsele, Hermann
A1  - Rasche, Leo
A1  - Kortüm, Martin
T1  - Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib‐resistant non‐nodal leukemic mantle cell lymphoma
JF  - European Journal of Haematology
N2  - We herein report the case of a 73‐year‐old male patient who was diagnosed with leukemic non‐nodal MCL. This patient had received six cycles of bendamustine, which resulted in a transient remission, and a second‐line therapy with ibrutinib, which unfortunately failed to induce remission. We started a treatment with single‐agent obinutuzumab at a dose of 20 mg on day 1, 50 mg on day 2‐4, 330 mg on day 5, and 1000 mg on day 6. The laboratory analysis showed a rapid decrease of leukocyte count. Four weeks later, we repeated the treatment with obinutuzumab at a dose of 1000 mg q4w and started a therapy with venetoclax at a dose of 400 mg qd, which could be increased to 800 mg qd from the third cycle. This combination therapy was well tolerated. The patient achieved a complete remission (CR) after three cycles of obinutuzumab and venetoclax. To date, the patient has a progression‐free survival of 17 months under ongoing obinutuzumab maintenance q4w. This is the first report about obinutuzumab and venetoclax induced CR in rituximab‐intolerant patient with an ibrutinib‐resistant MCL. This case suggests that obinutuzumab‐ and venetoclax‐based combination therapy might be salvage therapy in patients with ibrutinib‐resistant MCL.
KW  - mantle cell lymphoma
KW  - obinutuzumab
KW  - venetoclax
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-215513
VL  - 104
IS  - 4
SP  - 352
EP  - 355
ER  - 
TY  - JOUR
A1  - Loda, Sophia
A1  - Krebs, Jonathan
A1  - Danhof, Sophia
A1  - Schreder, Martin
A1  - Solimando, Antonio G.
A1  - Strifler, Susanne
A1  - Rasche, Leo
A1  - Kortüm, Martin
A1  - Kerscher, Alexander
A1  - Knop, Stefan
A1  - Puppe, Frank
A1  - Einsele, Hermann
A1  - Bittrich, Max
T1  - Exploration of artificial intelligence use with ARIES in multiple myeloma research
JF  - Journal of Clinical Medicine
N2  - Background: Natural language processing (NLP) is a powerful tool supporting the generation of Real-World Evidence (RWE). There is no NLP system that enables the extensive querying of parameters specific to multiple myeloma (MM) out of unstructured medical reports. We therefore created a MM-specific ontology to accelerate the information extraction (IE) out of unstructured text. Methods: Our MM ontology consists of extensive MM-specific and hierarchically structured attributes and values. We implemented “A Rule-based Information Extraction System” (ARIES) that uses this ontology. We evaluated ARIES on 200 randomly selected medical reports of patients diagnosed with MM. Results: Our system achieved a high F1-Score of 0.92 on the evaluation dataset with a precision of 0.87 and recall of 0.98. Conclusions: Our rule-based IE system enables the comprehensive querying of medical reports. The IE accelerates the extraction of data and enables clinicians to faster generate RWE on hematological issues. RWE helps clinicians to make decisions in an evidence-based manner. Our tool easily accelerates the integration of research evidence into everyday clinical practice.
KW  - natural language processing
KW  - ontology
KW  - artificial intelligence
KW  - multiple myeloma
KW  - real world evidence
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-197231
SN  - 2077-0383
VL  - 8
IS  - 7
ER  -